Sona Deshmukh, MBBS, MPH

CRS:

BJMC

Role:

Research Staff

Position:

Study Coordinator

Dr. Deshmukh is Study Coordinator for the Tuberculosis-Diabetes study at the Byramjee Jeejeebhoy Government Medical College-JHU Clinical Research Site, funded by the NIH/National Institute of Allergy and Infectious Diseases (NIAID). Her research interests include the epidemiology of noncommunicable diseases and policy reforms for the same.

The BJGMC Clinical Research Site is a member of a the Baltimore-Washington-India Clinical Trials Unit, a collaborative research partnership among BJGMC, Johns Hopkins School of Medicine, and Whitman Walker Health in Washington, DC, to conduct clinical research for the world’s largest HIV therapeutic trial networks: the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric and Adolescent AIDS Clinical Trial Network (IMPAACT).

Dr. Deshmukh has more than five years of experience in public health, programme management, policy design, and community-based research studies for noncommunicable diseases. She has published two research publications. Following a short tenure as Medical Officer in a government hospital, she worked under the dynamic leadership of Dr. Abhay Bang for two years in their esteemed research organization SEARCH, in Gadchiroli, India. Here she designed, implemented, and managed various community-based research projects conducted in 86 villages in Gadchiroli.

Further she took the opportunity to work in the state health department for three years as District Programme Officer to implement and monitor the National Programme for Prevention and Control of Non Communicable Diseases in Chandrapur, Maharashtra. Following her field experience, she briefly served for six months as a senior consultant for public health to government of Maharashtra.

Dr. Deshmukh received a MBBS in medicine from Maharashtra University of Health Sciences in Nashik, India, and a Master of Public Health degree from Tata Institute of Social Sciences (TISS) in Mumbai, India.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

A5384: A Phase II, Randomized, Open-Label Trial of a...

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

Read More

Impact of Tuberculosis Infection on HIV-1 Antibody Response...

Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More